Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.43 |
| ▸ | NQO2 | P16083 | 3/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4838027 | 0.85 | CDK4 (0.49) | MTNR1ATRPV1CYP3A4 | |
| SCHEMBL4839942 | 0.83 | CA2 (0.45) | CTSSCTSK | |
| SCHEMBL4886128 | 0.81 | KMT2A (0.45) | TRPV1 | |
| SCHEMBL4835729 | 0.81 | MTNR1A (0.45) | MTNR1ANQO2CTSSCTSKCASP1 | |
| SCHEMBL4840448 | 0.81 | L3MBTL1 (0.43) | CYP3A4 | |
| SCHEMBL4838164 | 0.81 | NPC1 (0.48) | MTNR1AMTNR1B | |
| SCHEMBL4840798 | 0.80 | MMP2 (0.45) | — | |
| SCHEMBL4839501 | 0.79 | L3MBTL1 (0.49) | CTSSCTSKCYP3A4 | |
| SCHEMBL4831283 | 0.79 | CA2 (0.49) | CTSSCTSKCYP3A4 | |
| SCHEMBL4841261 | 0.78 | ABCB1 (0.46) | CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365091-B2 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | ENOBIA PHARMA (CA) | 2008-04-29 | — | — | US | disclosed |
| US-20060287280-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | ENOBIA PHARMA (CA) | 2006-12-21 | — | — | US | disclosed |
| US-7105539-B2 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | ENOBIA PHARMA (CA) | 2006-09-12 | — | — | US | disclosed |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | ENOBIA PHARMA (CA) | 2006-06-22 | — | — | US | disclosed |
| EP-1572645-A2 | DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX | Enobia Pharma Inc. (CA) | 2005-09-14 | — | — | EP | disclosed |
| US-20040186301-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | BIOMEP INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004050620-A2 | DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX | ENOBIA PHARMA (CA) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287280-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | GLS, SUCNR1, PGD | MTNR1A 3880/4885NQO2 309/4885CTSS 1630/4885 |
| US-20040186301-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | GLS, SUCNR1, PGD | MTNR1A 3835/4885NQO2 317/4885CTSS 1756/4885 |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | GLS, SUCNR1, GCDH | MTNR1A 3857/4885NQO2 253/4885CTSS 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.